Open AccessShort-Course Treatment of Visceral Leishmaniasis with Liposomal Amphotericin B (AmBisome)
Author(s) -
Robert N. Davidson,
L. di Martino,
Luigi Gradoni,
Raffaella Giacchino,
Giovanni Battista Gaeta,
R. Pempinello,
Silvestro Scotti,
Antonio Cascio,
Elio Castagnola,
Antonella Maisto,
Marina Gramiccia,
Domenico Di Caprio,
Robert J. Wilkinson,
A. D. M. Bryceson
Publication year - 1996
Publication title -
clinical infectious diseases/clinical infectious diseases (online. university of chicago. press)
Language(s) - English
Resource type - Journals
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/clinids/22.6.938
Subject(s) - medicine , leishmania infantum , visceral leishmaniasis , amphotericin b , clearance , adverse effect , leishmaniasis , antifungal , immunology , urology , dermatology
We evaluated liposomal amphotericin B (AmBisome; Vestar, San Dimas, CA) administered to 88 immunocompetent patients (56 children) with visceral leishmaniasis (VL) caused by Leishmania infantum. Thirteen patients received 4 mg/kg on days 1-5 and 10 (total dose, 24 mg/kg), and all were cured; 42 received 3 mg/kg on days 1-5 and 10 (18 mg/kg), and 41 were cured; 32 received 3 mg/kg on days 1-4 and 10 (15 mg/kg), and 29 were cured (amastigotes were not cleared from 1 child, and 2 relapsed). One adult was cured with a total dose of 12mg/kg. The four children who were not cured received 3 mg/kg for 10 days; none had further relapses. There were no significant adverse events. For VL due to L. infantum, we recommended a total dose of AmBisome of > or = 20 mg/kg, given in > or = 5 doses of 3-4 mg/kg over > or = 10 days.